NICE Surgical Secures Patent for Innovative Minimally Invasive Surgical Device

On July 20, 2026, NICE Surgical Solutions Pte Ltd, a progressive clinical-stage medical device company, announced that it has received U.S. Patent No. 12,661,097 B2. This patent is for a groundbreaking extracting device that complements their novel purse-string stapler, fundamentally transforming the landscape of colorectal surgery by significantly reducing the need for surgical incisions.

A Leap Forward in Surgery

The new patent protects the unique design of NICE's extraction device along with its introducer. This innovative technology enables the removal of excised colon tissue via the intra-anal canal, making procedures less invasive and enhancing patient safety. With this advancement, surgeries can now be performed completely intracorporeally, eliminating the abdominal incisions that are standard in current practices.

The co-founder of NICE Surgical and renowned colorectal surgeon, Dr. Eric Haas, expressed his enthusiasm regarding this innovation. He emphasizes that true advancement in colorectal surgery is not solely about new technology but rather about enhancing safety, expediting recovery, and ultimately improving patient quality of life. These innovations underscore NICE Surgical's commitment to developing proprietary medical solutions that serve this very purpose.

Underlining the Importance of Innovation

Haim Brosh, CEO of Trendlines Medical—NICE Surgical's parent company—added that the award of the patent underscores NICE Surgical's dedication to thoughtful innovation and exceptional design in medical technology. The dynamic duo of the patent for the extracting device and the previously patent-protected purse-string stapler reinforces their leadership in creating enhanced solutions for medical practices.

In addition to this new patent, NICE Surgical is actively focused on developing its stapling device that facilitates two critical actions: dividing the bowel at the points of resection and placing a purse-string suture that prepares the bowel for Intra Corporeal Anastomosis (ICA). This dual function is vital in surgical procedures targeted at enhancing outcomes for patients undergoing colorectal surgery.

The Broader Impact

The implications of NICE Surgical's innovations stretch beyond just the technical specifications of their products. By reducing the invasiveness of colorectal surgery, there is a significant potential to lower the rates of postoperative complications, including infections, which are often tied to larger incisional procedures. As the medical community embraces these advancements, patients stand to benefit from shorter recovery times and lower overall risk during their surgeries.

The Trendlines Group—an investment company specializing in medical technology and agrifood innovation—continues to be a driving force behind NICE Surgical's growth. With operations spanning Israel and Singapore, Trendlines is adept at transforming initial innovations into substantial business ventures that significantly impact medical practices worldwide.

As NICE Surgical seeks to revolutionize colorectal surgery, its new U.S. patent serves as a testament to the groundbreaking work being done in medical technology. With its focus on safety, efficiency, and quality healthcare, NICE Surgical is poised to lead the next wave of innovation in surgical practices.

For further information, media can contact Eric Loh, CEO of Trendlines Medical Singapore, to learn more about this exciting development and its potential impacts on surgical procedures.

Media Contact: Eric Loh CEO Trendlines Medical Singapore [email protected]